Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.23 USD
Change Today -0.38 / -1.68%
Volume 383.2K
OMER On Other Exchanges
Symbol
Exchange
Berlin
As of 3:18 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Open
$22.36
Previous Close
$22.61
Day High
$22.72
Day Low
$21.50
52 Week High
03/5/15 - $27.64
52 Week Low
05/21/14 - $9.76
Market Cap
840.3M
Average Volume 10 Days
489.8K
EPS TTM
$-2.22
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

103 Employees
Last Reported Date: 03/16/15
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $664.6K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $79.7K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2013.

omeros corp (OMER) Key Developments

Omeros Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Omeros Corporation reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $180,000 compared to $160,000 a year ago. Loss from operations was $19,975,000 compared to $13,902,000 a year ago. Net loss was $20,713,000 compared to $1,845,000 a year ago. Basic and diluted net loss per share was $0.61 compared to $0.05 a year ago. For the full year, the company reported revenue of $539,000 compared to $1,600,000 a year ago. Loss from operations was $70,008,000 compared to $50,516,000 a year ago. Net loss was $73,673,000 compared to $39,796,000 a year ago. Basic and diluted net loss per share was $2.22 compared to $1.39 a year ago. The decrease for the full year 2014 was due to lower revenue recognized from the GPCR program funding agreements with Vulcan and LSDF, and the company will not recognize any additional revenue under these agreements in future periods.

Omeros Corporation to Report Q4, 2014 Results on Mar 16, 2015

Omeros Corporation announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 16, 2015

Omeros Corporation, Q4 2014 Earnings Call, Mar 16, 2015

Omeros Corporation, Q4 2014 Earnings Call, Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $22.23 USD -0.38

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,430.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,512.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.